Search PubMed⌕ Search

Biomedical subjects

M Sako

Publications and source records attributed to M Sako.

At least 127 records · Page 7Linked to original sources
PubMed1988

[Pharmacokinetics and urinary excretion of aspoxicillin after consecutive administration at a dose of 4 grams].

Aspoxicillin (ASPC), a new injectable penicillin, was administered to 5 healthy male adult volunteers once a day at a daily dose of 4 g for 5 consecutive days to study its absorption and excretion. The results of this study are summarized as follows: 1. In consecutive administration of ASPC for 5 successive days, no remarkable changes were observed in serum concentrations and urinary excretion after each administration of ASPC. Therefore, no tendency of accumulation of the drug was recognized. 2. The serum ASPC concentration showed its peak values ranged from 212.3 to 224.8 micrograms/ml at completion of the intravenous drip infusion of ASPC. 3. Urinary recovery rates of ASPC ranged from 70 to 80%. 4. There were neither abnormal findings in subjective and objective symptoms nor abnormal values in physical and clinical laboratory test due to the administration of ASPC.

Adult↗
PubMed1986

[Embolotherapy of hepatomas using ferromagnetic microspheres, its clinical evaluation and the prospect of its use as a vehicle in chemoembolo-hyperthermic therapy].

Ferromagnetic microembolization (FME) was applied to patients with hepatoma, using iron microspheres (30-50 mu), suspended in aqueous polysaccharide solution; dextran 40 (12%), sodium carboxymethyl-cellulose (2%) in saline solution. Hepatic arterial infusion of this agent was performed under external magnetic control to confine iron microspheres within the target organs. The therapeutic effect of this procedure on 44 patients with hepatoma was evaluated in relation to the stages of the disease, showing excellent, improved survival terms; survival rates calculated by Kaplan-Meier's method for patients with stage I to III hepatomas were 80% (1 year), 50% (2 years) and 30% (3 years). In order to extend the therapeutic effect of this procedure further, polysaccharide solution was also utilized as a carrier of anti-cancer agents. Serologic and histologic data in experimental animals showed evidence of prolonged release of Mitomycin from polysaccharide solution admixed, indicating its potential use as a method of chemo-embolization. In addition to this, we have also been developing the induction heating of the magnetic microspheres, introduced into the lesion by means of FME, to heat the lesion selectively. The procedure is still in the experimental phase. However, recent results strongly suggest the possibility of its clinical use. In conclusion, we consider FME to be one of the most reliable and potentially valuable methods for extending the capability of multidisciplinary treatment of hepatoma.

Animals↗
PubMed1986

Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.

For the purpose of clinical application to the therapy of human leukemia and lymphosarcoma, L-asparaginase from Escherichia coli was modified with 2,4-bis(O-methoxypolyethylene glycol)-6-chloro-s-triazine (activated PEG2) by an improved method, which involves a purification step of activated PEG2 by gel filtration. The PEG2-modified asparaginase retained approximately 30% (73 IU/mg of protein) of the enzymic activity of the native enzyme, while it had almost wholly lost the immunoreactivity towards anti-asparaginase antibodies. The modified enzyme retained the characteristics of the native enzyme in terms of the pH- and temperature-dependencies of activity and stability, and the Km value for L-asparagine. Administration of the modified enzyme to a dog with spontaneous lymphosarcoma induced complete remission without any toxic side effects. Seven children with multiple relapses of acute leukemia were treated with a regimen of cycles of methotrexate and native asparaginase. Three of these children developed anaphylactic shock. In contrast to the native enzyme, the successive administration of PEG2-modified asparaginase to those three patients was therapeutically effective without causing any allergic reaction.

Adolescent↗
PubMed1986

[A case of prostatic leiomyosarcoma].

A case of a 19-year-old male with leiomyosarcoma of the prostate is reported. He visited our hospital with the chief complaint of urinary retention in December, 1983. Following overall examination, needle biopsy of the prostate gland was performed with the suspicion of sarcoma. Histology of the prostate revealed leiomyosarcoma. Two courses of combined chemotherapy were given, but the tumor continued to enlarge. The patient died in April, 1984, 5 months after the appearance of the first symptom.

Adult↗
PubMed1986

[Pharmacokinetics of cefixime in patients with impaired renal function].

Cefixime (CFIX) was given orally in a single dose of 100 mg to 7 patients with varying degrees of impaired renal function (Ccr 12.0-56.7 ml/min) and serum concentrations and urinary excretion rates were measured with time for the first 24 hours by the bioassay method to investigate in vivo pharmacokinetics of the drug. The results obtained are summarized as follows. The mean peak serum concentration of CFIX in 3 patients with moderately impaired renal function (group I: Ccr greater than or equal to 30-less than 60 ml/min) was 2.04 micrograms/ml at 6 hours after dosing and gradually declined to 0.10 microgram/ml at 24 hours after dosing. The half-life was 4.15 hours. The mean peak serum concentration of CFIX achieved was 2.27 micrograms/ml at 8 hours after dosing in 4 patients with severely impaired renal function (group II: Ccr greater than or equal to 10-less than 30 ml/min) and the concentration of CFIX was 0.99 microgram/ml even after 24 hours. The half-life was prolonged to 11.05 hours. There was no great difference between groups I and II in the first 24-hour urinary excretion rates. However, the first 4-hour urinary excretion accounted for 2.14% of the administered dose of CFIX in group I but only 0.47% in group II. Urinary concentrations of CFIX peaked at 4-6 hours after dosing in both groups, and thereafter gradually decreased in group I. Whereas, they did not decline much in group II until 24 hours after dosing.(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Oral↗